Literature DB >> 20724727

Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma.

Ian M Thompson, Donna P Ankerst, Catherine M Tangen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20724727      PMCID： PMC2935478          DOI： 10.1093/jnci/djq313

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Ziding Feng; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.

Authors:  Ola Bratt; Hans Garmo; Jan Adolfsson; Anna Bill-Axelson; Lars Holmberg; Mats Lambe; Pär Stattin
Journal:  J Natl Cancer Inst       Date:  2010-08-19       Impact factor: 13.506

3.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.

Authors:  Isaac J Powell; Cathryn H Bock; Julie J Ruterbusch; Wael Sakr
Journal:  J Urol       Date:  2010-03-17       Impact factor: 7.450

4.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; M Scott Lucia; Phyllis J Goodman; John J Crowley; Howard L Parnes; Charles A Coltman
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

5.  Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006.

Authors:  Louie E Ross; Yhenneko J Taylor; Lisa C Richardson; Daniel L Howard
Journal:  J Natl Med Assoc       Date:  2009-04       Impact factor: 1.798

6.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

7.  Probabilities of eventually developing or dying of cancer--United States, 1985.

Authors:  H Seidman; M H Mushinski; S K Gelb; E Silverberg
Journal:  CA Cancer J Clin       Date:  1985 Jan-Feb       Impact factor: 508.702

8.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245
  8 in total
  3 in total

1.  Familial risk and familial survival in prostate cancer.

Authors:  Kari Hemminki
Journal:  World J Urol       Date:  2011-11-25       Impact factor: 4.226

2.  Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests.

Authors:  Tao Liu; Mahmud Hossain; Athena A Schepmoes; Thomas L Fillmore; Lori J Sokoll; Scott R Kronewitter; Grant Izmirlian; Tujin Shi; Wei-Jun Qian; Robin J Leach; Ian M Thompson; Daniel W Chan; Richard D Smith; Jacob Kagan; Sudhir Srivastava; Karin D Rodland; David G Camp
Journal:  J Proteomics       Date:  2012-02-13       Impact factor: 4.044

Review 3.  Key Enabling Technologies for Point-of-Care Diagnostics.

Authors:  Elisabetta Primiceri; Maria Serena Chiriacò; Francesca M Notarangelo; Antonio Crocamo; Diego Ardissino; Marco Cereda; Alessandro P Bramanti; Marco A Bianchessi; Gianluigi Giannelli; Giuseppe Maruccio
Journal:  Sensors (Basel)       Date:  2018-10-24       Impact factor: 3.576
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.